Drugs / PegIFN-alpha-2a
PegIFN-alpha-2a
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02742324 | Mar 2016 → Dec 2021 | myelofibrosis | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05005507 | Nov → Dec 2021 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04667104 | Feb 2021 → May 2022 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04439539 | Sep 2020 → Aug 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00887081 | Jan 2009 → Dec 2013 | hemoglobinopathy | Azienda Ospedaliera V. Cervello | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04585789 Background | Mar 2021 → Feb 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01290731 Background | Jan 2011 → Aug 2012 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFN-alpha2a | “Peg-IFN-alpha-2a is administered subcutaneously once a week.” NCT02742324 ↗ |
| Known as | PegIFN-α2a | “evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in patients with virologically suppressed CHB.” PMID 40919077 ↗ Jul 20251“standard of care (SoC), PegIFNα-2a (P) and ribavirin (R)” NCT01290731 ↗ |
| Known as | Pegylated interferon | “Pegylated interferon (pegIFN alpha-2a)” NCT01290731 ↗ |
| Known as | pegylated interferon alpha-2a | “evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in patients with virologically suppressed CHB.” PMID 40919077 ↗ Jul 2025 |
| Modality | Protein / enzyme biologic | “combination therapy with pegylated interferon and ribavirin” NCT00887081 ↗ |
| Route | Subcutaneous | “180 mcg injected subcutaneously (by a syringe under the skin) once weekly” NCT01290731 ↗ |